Advertisement

Efficacy of plasma exchange with a high dose of acyclovir for disseminated varicella infection

  • Jun Aoyagi
  • Takahiro KanaiEmail author
  • Tomomi Maru
  • Jun Odaka
  • Takashi Saito
  • Hiroyuki Betsui
  • Takanori Yamagata
Case Report
  • 6 Downloads

Abstract

In individuals treated with immunosuppressive therapies, the varicella-zoster virus (VZV) infection can become disseminated and lead to a life-threatening condition. There is currently no established treatment strategy for this life-threatening condition. Here, we describe a case where plasma exchange (PE) with a high dose of acyclovir (ACV) ameliorated the severe effects, including VZV-hemophagocytic lymphohistiocytosis (VZV-HLH) and disseminated intravascular coagulation (DIC), in a 9-year-old girl with steroid-dependent nephrotic syndrome. This 9-year-old girl experienced frequent relapse steroid-dependent nephrotic syndrome. She had been treated with steroids, tacrolimus, mizoribine, and rituximab. She had not previously received a varicella vaccine. She was admitted with only one vesicular rash. At admission, a serum test revealed 1.6 × 106 copies/mL of VZV DNA. The patient rapidly developed VZV-HLH and DIC. A combination of a high dose of ACV, immunoglobulin, and steroid pulse therapy could not improve these severe complications. Therefore, PE was applied. PE with a high dose of ACV successfully reduced serum VZV DNA from 7.5 × 106 to 2.8 × 104 copies/mL. This reduction in the VZV DNA copy number suggested that the combination of PE and a high dose of ACV was effective in treating a disseminated VZV infection. To the best of our knowledge, this is the first report showing that PE with a high dose of ACV ameliorated the severe complications of disseminated VZV by reducing the VZV DNA copy number.

Keywords

Acyclovir Disseminated varicella infection Plasma exchange Frequent relapse steroid-dependent nephrotic syndrome Vzv-hemophagocytic lymphohistiocytosis VZV DNA copy number 

Notes

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of Jichi Medical University at which the studies were conducted (IRB approval number A19-009) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Yamada N, Sanada Y, Okada N, Wakiya T, Ihara Y, Urahashi T, et al. Successful rescue of disseminated varicella infection with multiple organ failure in a pediatric living donor liver transplant recipient: a case report and literature review. Virol J. 2015;12:91.CrossRefGoogle Scholar
  2. 2.
    Kim JH, Kwon DH, Bae EY, Han SB, Lee JW, Chung NG, et al. Use of intravenous immunoglobulin in a disseminated varicella infection in an immunocompromised child. Korean J Pediatr. 2014;57(8):370–3.CrossRefGoogle Scholar
  3. 3.
    Hirose I, Ymamaguchi H, Inaguma D, Ono K, Shimada S, Kawada J, et al. Fatal varicella infection in a girl with systemic lupus erythematosus after oral acyclovir prophylaxis. Eur J Pediatr. 2006;165(4):280–1.CrossRefGoogle Scholar
  4. 4.
    Lee C, Koike M, Oshimi K, Terakura S, Kodera Y. Acyclovir combined with plasma exchange for disseminated varicella-zoster virus infection after bone marrow transplantation. Rinsho Ketsueki. 2006;47(3):210–3.Google Scholar
  5. 5.
    Gur G, Cakar N, Uncu N, Ayar G, Basaran O, Taktak A, et al. Hemophagocytic lymphohistiocytosis secondary to Varicella zoster infection in a child with Henoch-Schonlein purpura. Pediatr Int. 2015;57(2):e37–e3838.CrossRefGoogle Scholar
  6. 6.
    Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2012;27(11):2073–9.CrossRefGoogle Scholar
  7. 7.
    Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRefGoogle Scholar
  8. 8.
    Karlsson H, Truedsson L, Nassberger L. The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. Immunol Lett. 1991;30(1):129–32.CrossRefGoogle Scholar
  9. 9.
    van der Werff ten Bosch JE, Kollen WJ, Ball LM, Brinkman DM, Vossen AC, Lankester AC, et al. Atypical varicella zoster infection associated with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009;53(2):226–8.CrossRefGoogle Scholar
  10. 10.
    Hasegawa T, Kurokawa M, Yukawa TA, Horii M, Shiraki K. Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Res. 1995;27(3):271–9.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  • Jun Aoyagi
    • 1
  • Takahiro Kanai
    • 1
    Email author
  • Tomomi Maru
    • 1
  • Jun Odaka
    • 1
  • Takashi Saito
    • 1
  • Hiroyuki Betsui
    • 1
  • Takanori Yamagata
    • 1
  1. 1.Department of PediatricsJichi Medical UniversityTochigiJapan

Personalised recommendations